Overview: What Centene Announced
Centene Corporation , one of the largest managed care organizations in the United States, has officially reaffirmed its 2026 full-year earnings guidance as its senior management team prepares to meet with investors during the week of February 23, 2026. The announcement comes as a reassuring signal to shareholders and market analysts who have closely monitored the company’s recovery trajectory following a difficult fiscal year in 2025.
The reaffirmation was disclosed through Centene’s latest Form 8-K filing with the U.S. Securities and Exchange Commission, reinforcing the company’s commitment to financial transparency and consistent communication with the investment community. Centene is one of the country’s leading providers of government-sponsored healthcare programs, managing coverage for Medicaid, the Children’s Health Insurance Program (CHIP), Medicare Advantage, and individual ACA marketplace plans.
2026 Earnings Guidance Details
Key EPS Targets Reaffirmed
Centene’s management has reconfirmed the following full-year 2026 financial guidance targets:
GAAP Diluted EPS: Greater than $1.98 Adjusted Diluted EPS: Greater than $3.00 Premium and Service Revenue Range: $170 billion to $174 billion Health Benefits Ratio (HBR): 90.9% to 91.7%
The adjusted diluted EPS target of more than $3.00 represents a significant improvement of over 40% compared to the full-year 2025 adjusted diluted EPS of $2.08. CEO Sarah M. London described the guidance as “important progress toward restoring the enterprise’s embedded earnings power,” while reinforcing the company’s mission to provide access to affordable, high-quality care for its members.
Revenue Guidance Context
While the 2026 premium and service revenue guidance of $170–$174 billion appears lower than the $194.8 billion in total revenues reported for 2025, the company attributes this primarily to anticipated Medicaid membership declines of approximately 5–6% and the divestiture of its remaining Magellan Health businesses. Management remains confident that revenue quality and margin performance will improve meaningfully throughout 2026.
Understanding Non-GAAP Financial Measures
Why Centene Uses Non-GAAP Metrics
As part of its guidance disclosure, Centene has explained why it provides certain non-GAAP financial measures alongside GAAP results. The company believes these figures offer investors a clearer view of ongoing operations and allow for more consistent performance comparison across reporting periods.
What Is Excluded From Adjusted EPS
The adjusted diluted EPS calculation excludes the following items:
- Amortization of acquired intangible assets
- Acquisition and divestiture-related expenses
- Non-cash impairment charges (including the $513 million charge related to the Magellan Health divestiture)
- Other non-recurring items
These exclusions allow management and investors to evaluate the core health plan business performance without the distortion caused by one-time events. Non-GAAP metrics are also used internally by Centene for performance evaluation, operational planning, and determining employee incentive compensation.
For a complete reconciliation of GAAP diluted EPS to adjusted diluted EPS, investors are directed to the press release filed as Exhibit 99.1 to the Form 8-K on February 6, 2026.
2025 Financial Performance in Review
A Challenging Year With Positive Momentum
Centene’s full-year 2025 results were heavily impacted by a non-cash goodwill impairment charge of approximately $6.7 billion, resulting in a GAAP diluted loss per share of $(13.53). However, the adjusted diluted EPS of $2.08 for the full year came in slightly ahead of expectations, signaling that the underlying business held up better than feared.
Q4 2025 Operational Highlights
In the fourth quarter of 2025, Centene reported revenue of $49.73 billion, surpassing analyst expectations of $48.41 billion. Key operational metrics included a consolidated Health Benefits Ratio (HBR) of 94.3%, with Medicaid HBR improving sequentially to 93.0% — a 40 basis point improvement compared to Q3 2025.
The company also maintained disciplined cost management, reporting an adjusted SG&A expense ratio of 7.4% for the full year. Cash flow from operations reached $5.1 billion for 2025, supported by improved pharmacy rebate timing and higher medical claims liabilities driven by increased membership.
Segment Outlook for 2026
Medicaid: Stabilization and Rate Recovery
Centene’s Medicaid segment, the backbone of its business as the largest Medicaid managed care company in the U.S., is expected to maintain a stable Health Benefits Ratio year-over-year in 2026. Management has been actively engaging with state partners to ensure Medicaid payment rates reflect the elevated acuity and trend increases observed in recent years.
Marketplace: Margin Recovery Underway
In the Commercial segment, primarily consisting of ACA Marketplace plans, Centene anticipates approximately a 4% pre-tax margin for 2026. While the company saw higher-than-expected Commercial HBR in Q4 2025 due to costs related to the No Surprises Act and a 2023 CMS reconciliation, management expressed confidence that pricing actions taken during open enrollment will support margin improvement throughout 2026.
Medicare: Progress Toward Breakeven
Centene’s Medicare segment remains a work in progress. The company targets a 2% pre-tax margin for its Medicare Prescription Drug Plan (PDP) business in 2026, while Medicare Advantage is expected to approach but not yet reach breakeven. Notably, the absence of a premium deficiency reserve in 2026 indicates that the Medicare Advantage business is no longer operating at a loss on the margin.
Investor Meetings and Market Reaction
Management to Meet With Investors
Centene’s senior management team, led by CEO Sarah M. London and CFO Drew Asher, is scheduled to meet with investors throughout the week of February 23, 2026. The primary agenda for these meetings is to reaffirm the company’s 2026 financial guidance and outline the strategic path toward earnings restoration.
Seasonality of Earnings in 2026
Management has indicated that the distribution of 2026 adjusted EPS will be front-loaded, with the majority expected in Q1, a step down in Q2, approximately break-even in Q3, and a loss expected in Q4. This seasonal pattern is driven primarily by the benefit design of Marketplace and Prescription Drug Plan products, which typically carry lower Health Benefits Ratios in the early part of the year.
Analyst Ratings and Market Sentiment
Mixed but Cautiously Optimistic
Centene’s 2026 guidance reaffirmation has been met with cautious optimism from Wall Street. As of recent reports, three investment analysts have assigned a Buy rating, while fourteen hold a Hold rating, and three carry a Sell rating. The consensus target price stands at approximately $40.81 per share.
Notable recent analyst actions include JPMorgan Chase & Co. raising its price target on CNC from $38.00 to $45.00 with a “neutral” rating, and Deutsche Bank lifting its target from $32.00 to $39.00. Oppenheimer has maintained an “outperform” rating with a $45.00 price target, representing one of the more bullish calls on the stock.
Centene’s results were notably described by JP Morgan analyst John Stansel as providing “some relief for investors” following Molina Healthcare’s dramatic earnings miss and sharply lowered 2026 outlook.
What This Means for CNC Investors
A Recovery Story in Progress
Centene’s reaffirmation of its 2026 guidance marks a meaningful turning point in what has been a difficult period for the healthcare giant. The company’s ability to project over 40% adjusted EPS growth year-over-year, while peers like Elevance and Molina are forecasting earnings declines, positions Centene as a relative outperformer within the managed care sector.
Investors evaluating CNC will want to monitor Medicaid rate negotiations with state partners, Marketplace membership mix trends, progress in Medicare Advantage toward breakeven, and the completion of the Magellan Health divestiture. While policy uncertainty and cost volatility remain genuine risks, Centene’s management has signaled confidence that the decisive operational actions taken in the back half of 2025 are bearing fruit — and that 2026 represents a firm step toward restoring the company’s long-term earnings power.
